Reports

 

• Gaming the system: An overview of originator companies' evergreening strategies used to hinder access to generic and biosimilar products (January 2025)
  
  
• IGBA Drug Shortages Workstream - Report to the World Health Organization (November 2022)
  
  
• IGBA Biosimilars Committee White Paper: Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline (November 2022)

• IGBA Biosimilars Committee White Paper: A Biosimilar medicines Access Policy Blueprint (October 2021)

• IGBA Whitepaper: a Vision for the Global Generic and Biosimilar Medicines Industry (May 2021)
  
  
• The positive impact that generic and biosimilar medicines have on patients and health systems (December 2020)
  
  
• IQVIA study: Impact of free trade agreements (FTAs) on generic and biosimilar medicines markets (October 2020)
  
  
• The Unspoken Cost of Pharma IP Protections from Trade Agreements (Infographic)
  
  
• IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)
  
  
• IGBA Trade Principles (June 2019)
  
  
• IGBA Preserving Sustainable Competition and Preventing Drug Shortages - FDA Docket Submission Final (January 2019)